Lung Cancer Research News
Ongoing, sourced coverage of newly published lung cancer trial results and research developments. Sorted newest first. Each article links to its original sources.
USC Study Examines Diet Patterns in Young, Non-Smoking Lung Cancer Patients
A University of Southern California study of 187 people diagnosed with lung cancer by age 50, most of them never-smokers, found their reported pre-diagnosis diets scored higher on a standard healthy-eating index than the national average — a correlation researchers say needs far more investigation.
Read More →Study Finds Genomic Evidence Linking Air Pollution to Lung Cancer in Never-Smokers
A study published in Nature found genomic mutation patterns in never-smoker lung tumors that resemble damage signatures associated with air pollution exposure, adding mechanistic evidence to a long-observed epidemiological trend.
Read More →Small Cell Lung Cancer Research Turns to Molecular Subtypes and Brain Metastases
New analysis from the DeLLphi-304 trial examined how tarlatamab performs against brain metastases in small cell lung cancer, while separate research previewed how molecular SCLC subtypes may predict which patients benefit most from maintenance therapy.
Read More →TRITON Study Targets Lung Cancers That Resist Standard Immunotherapy
Interim results from the phase 2b TRITON study suggest that adding tremelimumab to durvalumab plus chemotherapy may help nonsquamous metastatic NSCLC with STK11, KEAP1, and/or KRAS mutations — a group that has historically responded poorly to standard immunotherapy combinations.
Read More →Chemotherapy-Free Combination Shows Early Promise for KRAS G12C-Mutant Lung Cancer
Early data from the KRAScendo-170 study testing divarasib, a next-generation KRAS G12C inhibitor, combined with pembrolizumab reported a roughly 70% response rate and 19.3-month median progression-free survival in PD-L1-positive tumors, without chemotherapy.
Read More →Ivonescimab Trial Reports Survival Edge Over Standard Immunotherapy in Squamous Lung Cancer
The phase 3 HARMONi-6 trial found that ivonescimab, a dual PD-1/VEGF-targeting antibody, extended median overall survival to 27.9 months compared with 23.7 months for a standard checkpoint inhibitor, both combined with chemotherapy, in advanced squamous NSCLC.
Read More →Bispecific Antibody Pumitamig Shows 70% Response Rate in Early NSCLC Trial Data
Pumitamig, an investigational antibody designed to block both PD-L1 and VEGF-A at once, showed a 70% overall response rate and 100% disease control rate in a phase 2 dose-optimization study of treatment-naive advanced NSCLC.
Read More →ASCO 2026: Updated Data Show Extended Survival With Amivantamab-Lazertinib in Atypical EGFR-Mutant Lung Cancer
New data presented at the 2026 ASCO Annual Meeting show a median overall survival of 41 months for first-line amivantamab plus lazertinib in patients with atypical EGFR mutations — a group that has historically had weaker outcomes than classical EGFR-mutant disease.
Read More →Immunotherapy Before Surgery Helps More Stage III Lung Cancer Patients Become Operable, Trial Finds
An Alliance Foundation Trials study (AFT-46/CHIO3) found that combining chemotherapy and immunotherapy before surgery helped 81% of enrolled patients with locally advanced NSCLC undergo surgery, with 73% achieving complete clearance of affected lymph nodes.
Read More →UCL Researchers Call for More Funding to Study Lung Cancer in Never-Smokers
A review published in Trends in Cancer calls for increased funding for screening and study of lung cancer in never-smokers, noting that cases in the UK study doubled between 2008 and 2014 while screening resources remain overwhelmingly directed at smokers.
Read More →